Compare Amphastar Pharmaceuticals Inc (AMPH) vs DoorDash Inc (DASH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs DoorDash Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while DoorDash Inc trades at $191.99 (market cap $83.58B). The key difference: DoorDash Inc is far larger — about 101.2× Amphastar Pharmaceuticals Inc's market cap, and DoorDash Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | DASH | |
|---|---|---|
Market Cap | $826.08M | $83.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $281.74 |
52-Week Low | $16.87 | $146.60 |
Enterprise Value | $1.22B | $81.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
DoorDash (DASH) trades at $191.82, down 0.28% on the day, with a bullish technical signal and strong analyst support. The stock shows robust revenue growth, reaching $13.72 billion in 2025, and has turned profitable with a net income margin of 6.29%. Recent news highlights expansion into grocery delivery and AI integration, while technical indicators suggest key resistance near $200.
The outlook remains positive due to market dominance and international expansion, but risks include intense competition and valuation concerns with a P/E of 90.91. Analysts project a consensus price target of $231.50, implying significant upside, though upcoming Q2 2026 earnings on August 5 will be critical for momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →
